/ COGT
/ Market Analysis
Cogent Biosciences Stock Soars 120% on Positive Phase 3 Cancer Drug Results
Cogent Biosciences stock jumped 120% after positive Phase 3 PEAK trial results for its GIST drug bezuclastinib.
November 10, 2025